Bayer: Venous Thrombosis trials

The registry lists 23 Venous Thrombosis studies with Bayer as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 4Phase 2 5Phase 3 4No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)CompletedNCT02064439Phase 3Results posted
• Oral Rivaroxaban in Children With Venous ThrombosisCompletedNCT01684423Phase 2Results posted
• Switching Study From Warfarin to RivaroxabanCompletedNCT01507051Phase 1Results posted
• Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 InducerCompletedNCT00786422Phase 2Results posted
• Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill PatientsCompletedNCT00571649Phase 3Results posted
• Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT StudyCompletedNCT00440193Phase 3Results posted
• A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein ThrombosisCompletedNCT06149520Phase 2
• FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee ArthroplastyCompletedNCT03276143Phase 2
• A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active CancerCompletedNCT02742623
• Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)CompletedNCT02558465
• Bioequivalence Study of RivaroxabanCompletedNCT02537457Phase 1
• Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsCompletedNCT02537405Phase 1
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)CompletedNCT02468102
• Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care TherapyCompletedNCT02210819
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)CompletedNCT01947998
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)CompletedNCT01947985
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)CompletedNCT01947959
• Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)CompletedNCT01855100
• Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) IndicationCompletedNCT01805544
• Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care TherapyCompletedNCT01619007
• Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) PatientsCompletedNCT01516840Phase 3
• Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric SubjectsCompletedNCT01145859Phase 1
• Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)CompletedNCT00839163Phase 2